{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:07:54Z","timestamp":1786122474072,"version":"build-2736575974"},"reference-count":38,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Risk &amp; Safety in Medicine"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Stevens\u2013Johnson Syndrome is a type IV hypersensitivity mucocutaneous reaction characterised by a widespread desquamating rash, and is considered to be an emergency due to its potentially fatal complications. Drugs account for 50\u201380% of Stevens\u2013Jonson Syndrome\/Toxic Epidermal Necrolysis (SJS\/TEN) cases, with anticonvulsants, antibiotics, analgesics and allopurinol being the most common causative agents. Co-amoxiclav contains amoxicillin (a penicillin) and clavulanic acid (a beta-lactamase inhibitor) and is widely used in healthcare settings for treatment of common infections due to its relatively broad spectrum and good safety profile. However, few publications have attributed SJS\/TEN to co-amoxiclav administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case<\/jats:title>\n                    <jats:p>We describe the insidious development of Stevens\u2013Johnson Syndrome in a 98-year-old female after receiving intravenous and oral co-amoxiclav (amoxicillin\/clavulanic acid). The patient had received co-amoxiclav in prior hospital admissions with no reported complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome<\/jats:title>\n                    <jats:p>This was successfully treated with immunosuppressive therapies. The patient\u2019s frailty, as well as the exposed areas of skin and immunosuppression made her susceptible to a serious urinary tract infection and fall, which complicated her hospital stay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Co-amoxiclav, while generally a well-tolerated antibiotic, should be a recognised cause of Stevens\u2013Johnson syndrome, and care should be taken to prevent complications, especially in the elderly population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09246479261426749","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T22:51:16Z","timestamp":1771368676000},"page":"463-470","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["A case of delayed-onset Stevens\u2013Johnson syndrome following co-amoxiclav administration in a 98-year-old female"],"prefix":"10.1177","volume":"37","author":[{"given":"Gabriella","family":"Baldacchino","sequence":"first","affiliation":[{"name":"St. Vincent de Paul Hospital"},{"name":"Mater Dei Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Farrugia","sequence":"additional","affiliation":[{"name":"Mater Dei Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godfrey","family":"Baldacchino","sequence":"additional","affiliation":[{"name":"St. Vincent de Paul Hospital"},{"name":"Mater Dei Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1993.01680220104023"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000335627"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1586\/eci.11.66"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1991.01680050083008"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1990.01670250043005"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(96)00035-2"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5471765"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1992.00400190131024"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/428486a"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411103311906"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1884"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2007.02742.x"},{"key":"e_1_3_6_14_2","first-page":"e64717","article-title":"Exploring the therapeutic potential of high dose Co-amoxiclav (1 gm) in different clinical conditions: a review","volume":"16","author":"Jena D","year":"2024","unstructured":"Jena D, Kanti Ghosh T, Pal A, et al. Exploring the therapeutic potential of high dose Co-amoxiclav (1 gm) in different clinical conditions: a review. Cureus 2024; 16: e64717.","journal-title":"Cureus"},{"key":"e_1_3_6_15_2","doi-asserted-by":"crossref","unstructured":"Donati M Motola D Leone R et al. Liver injury due to amoxicillin vs. Amoxicillin\/Clavulanate: a subgroup analysis of a drug-induced liver injury case-control study in Italy. 2017. https:\/\/flore.unifi.it\/handle\/2158\/1104847 (accessed 17 April 2025).","DOI":"10.4172\/2475-3181.1000143"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-008-0785-7"},{"key":"e_1_3_6_17_2","first-page":"748","article-title":"Amoxycillin and clavulanic acid induced Stevens-Johnson syndrome: a case report","volume":"16","author":"Zaidi M","year":"2017","unstructured":"Zaidi M, Zaidi SK, Bhutto M, et al. Amoxycillin and clavulanic acid induced Stevens-Johnson syndrome: a case report. EXCLI J 2017; 16: 748\u2013751.","journal-title":"EXCLI J"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S422928"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_3_6_20_2","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"National Institute of Diabetes and Digestive and Kidney Diseases","year":"2012","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Adverse drug reaction probability scale (Naranjo) in drug induced liver injury. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. : National Institute of Diabetes and Digestive and Kidney Diseases, 2012. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548069\/ (accessed 18 May 2025)."},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.827"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.102367"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-017-0006-x"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri3547"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-017-0483-5"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.827660"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2012.12.017"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.949520"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2013.06.012"},{"key":"e_1_3_6_30_2","first-page":"e48728","article-title":"A compilation of drug etiologies of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"15","author":"Abulatan IT","year":"2023","unstructured":"Abulatan IT, Ben-David SG, Morales-Colon LA, et al. A compilation of drug etiologies of Stevens-Johnson syndrome and toxic epidermal necrolysis. Cureus 2023; 15: e48728.","journal-title":"Cureus"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm111"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.03.023"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.2332\/allergolint.55.17"},{"key":"e_1_3_6_34_2","unstructured":"Electronic Medicines Compendium. Co-amoxiclav 500\/100 mg powder for solution for injection\/infusion - summary of product characteristics (SmPC) - (emc) | 6959. 2023. https:\/\/www.medicines.org.uk\/emc\/product\/6959\/smpc (accessed 21 November 2025)."},{"key":"e_1_3_6_35_2","unstructured":"World Health Organization. The importance of pharmacovigilance. United Kingdom: World Health Organization https:\/\/www.who.int\/publications\/i\/item\/10665-42493 (2002)."},{"key":"e_1_3_6_36_2","volume-title":"Advances in Patient Safety: From Research to Implementation (Volume 1: Research Findings)","author":"Desikan R","year":"2005","unstructured":"Desikan R, Krauss MJ, Dunagan WC, et al. Reporting of adverse drug events: examination of a hospital incident reporting system. In: Henriksen K, Battles JB, Marks ES, et al. (eds). Advances in Patient Safety: From Research to Implementation (Volume 1: Research Findings). Agency for Healthcare Research and Quality (US), 2005. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK20453\/ (accessed 18 November 2025)."},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1867098"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy7030101"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1086\/510393"}],"container-title":["International Journal of Risk &amp; Safety in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09246479261426749","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09246479261426749","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09246479261426749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T10:20:39Z","timestamp":1786098039000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09246479261426749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/09246479261426749"],"URL":"https:\/\/doi.org\/10.1177\/09246479261426749","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/09246479261426749\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479261426749\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479261426749\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479261426749\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479261426749\/v3\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479261426749\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479261426749\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479261426749\/v3\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479261426749\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479261426749\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479261426749\/v1\/review1","asserted-by":"object"}]},"ISSN":["0924-6479","1878-6847"],"issn-type":[{"value":"0924-6479","type":"print"},{"value":"1878-6847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]}}}